Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities, 76654 [E8-29913]
Download as PDF
76654
Federal Register / Vol. 73, No. 243 / Wednesday, December 17, 2008 / Notices
shares up to 9.9 percent of the voting
shares of Chinatrust Financial Holding
Company, Ltd., Taipei, Taiwan, and
thereby acquire Chinatrust Bank
(U.S.A.), Torrance, California.
Board of Governors of the Federal Reserve
System, December 12, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–29913 Filed 12–16–08; 8:45 am]
Board of Governors of the Federal Reserve
System, December 12, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–29914 Filed 12–16–08; 8:45 am]
BILLING CODE 6210–01–S
BILLING CODE 6210–01–S
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2008–N–0439]
FEDERAL RESERVE SYSTEM
pwalker on PROD1PC71 with NOTICES
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than January 12, 2008.
A. Federal Reserve Bank of
Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261-4528:
1. Capital One Financial Corporation,
McLean, Virginia; to acquire Chevy
Chase Bank, Federal Savings Bank,
McLean, Virginia, and thereby engage in
operation a savings and loan association
pursuant to section 225.28(b)(4)(ii) of
Regulation Y.
VerDate Aug<31>2005
18:58 Dec 16, 2008
Jkt 217001
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Blood
Establishment Registration and
Product Listing, Form FDA 2830
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by January 16,
2009.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0052. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Blood Establishment Registration and
Product Listing, Form FDA 2830—
(OMB Control Number 0910–0052)—
Extension
Under section 510 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
360), any person owning or operating an
establishment that manufactures,
prepares, propagates, compounds, or
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
processes a drug or device must register
with the Secretary of Health and Human
Services, on or before December 31 of
each year, his or her name, place of
business, and all such establishments,
and must submit, among other
information, a listing of all drug or
device products manufactured,
prepared, propagated, compounded, or
processed by him or her for commercial
distribution. In part 607 (21 CFR part
607), FDA has issued regulations
implementing these requirements for
manufacturers of human blood and
blood products.
Section 607.20(a), in brief, requires
owners or operators of certain
establishments that engage in the
manufacture of blood products to
register and to submit a list of every
blood product in commercial
distribution. Section 607.21, in brief,
requires the owners or operators of
establishments entering into the
manufacturing of blood products to
register within 5 days after beginning
such operation and to submit a list of
every blood product in commercial
distribution at the time. If the owner or
operator of the establishment has not
previously entered into such operation
for which a license is required,
registration must follow within 5 days
after the submission of a biologics
license application. In addition,
establishments are required to register
annually between November 15 and
December 31 and update their blood
product listing every June and
December of each year. Section 607.22
requires the use of Form FDA 2830,
Blood Establishment Registration and
Product Listing, for initial registration,
for annual registration, and for blood
product listing. Section 607.25 indicates
the information required for
establishment registration and blood
product listing. Section 607.26, in brief,
requires certain changes to be submitted
on FDA Form 2830 as amendments to
the establishment registration within 5
days of such changes. Section 607.30(a),
in brief, indicates the information
required for owners or operators of
establishments to update their blood
product listing information every June
and December, or at the discretion of the
registrant at the time the change occurs.
Section 607.31 requires that additional
blood product listing information be
provided upon FDA request. Section
607.40, in brief, requires certain foreign
blood product establishments to register
and submit the blood product listing
information, and to provide the name
and address of the establishment and
the name of the individual responsible
for submitting blood product listing
E:\FR\FM\17DEN1.SGM
17DEN1
Agencies
[Federal Register Volume 73, Number 243 (Wednesday, December 17, 2008)]
[Notices]
[Page 76654]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-29913]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Notice of Proposals to Engage in Permissible Nonbanking
Activities or to Acquire Companies that are Engaged in Permissible
Nonbanking Activities
The companies listed in this notice have given notice under section
4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and
Regulation Y (12 CFR Part 225) to engage de novo, or to acquire or
control voting securities or assets of a company, including the
companies listed below, that engages either directly or through a
subsidiary or other company, in a nonbanking activity that is listed in
Sec. 225.28 of Regulation Y (12 CFR 225.28) or that the Board has
determined by Order to be closely related to banking and permissible
for bank holding companies. Unless otherwise noted, these activities
will be conducted throughout the United States.
Each notice is available for inspection at the Federal Reserve Bank
indicated. The notice also will be available for inspection at the
offices of the Board of Governors. Interested persons may express their
views in writing on the question whether the proposal complies with the
standards of section 4 of the BHC Act. Additional information on all
bank holding companies may be obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments regarding the applications must be
received at the Reserve Bank indicated or the offices of the Board of
Governors not later than January 12, 2008.
A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice
President) 701 East Byrd Street, Richmond, Virginia 23261-4528:
1. Capital One Financial Corporation, McLean, Virginia; to acquire
Chevy Chase Bank, Federal Savings Bank, McLean, Virginia, and thereby
engage in operation a savings and loan association pursuant to section
225.28(b)(4)(ii) of Regulation Y.
Board of Governors of the Federal Reserve System, December 12,
2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8-29913 Filed 12-16-08; 8:45 am]
BILLING CODE 6210-01-S